Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for Melasma
NCT03953209Phase 1Withdrawn
- Sponsor
- Medical University of South Carolina
- Start
- Mar 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of spironolactone in melasma (3 arms), sponsored by Medical University of South Carolina. Primary endpoint: Proportion of patients achieving clinical response at 12 weeks. Planned start Mar 2020; status: withdrawn.
02
Drugs
spironolactone
03
Conditions
melasma
Beyond the preview
Go deeper on NCT03953209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03953209.